Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Moderate Buy” by Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Free Report) has received an average rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $153.10.

Several research firms have commented on SRPT. Oppenheimer downgraded shares of Sarepta Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 31st. Morgan Stanley decreased their price objective on shares of Sarepta Therapeutics from $183.00 to $146.00 and set an “overweight” rating for the company in a research report on Tuesday, October 31st. Deutsche Bank Aktiengesellschaft began coverage on shares of Sarepta Therapeutics in a research report on Tuesday, December 12th. They set a “buy” rating and a $109.00 price objective for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $40.00 price objective (down from $166.00) on shares of Sarepta Therapeutics in a research report on Tuesday, October 31st. Finally, Barclays decreased their price objective on shares of Sarepta Therapeutics from $193.00 to $141.00 and set an “overweight” rating for the company in a research report on Thursday, November 2nd.

Get Our Latest Report on SRPT

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. US Bancorp DE grew its position in Sarepta Therapeutics by 16.1% during the fourth quarter. US Bancorp DE now owns 7,539 shares of the biotechnology company’s stock worth $727,000 after buying an additional 1,043 shares during the period. Cambridge Investment Research Advisors Inc. grew its position in Sarepta Therapeutics by 5.5% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 2,944 shares of the biotechnology company’s stock worth $284,000 after buying an additional 154 shares during the period. Aigen Investment Management LP acquired a new position in Sarepta Therapeutics during the fourth quarter worth about $315,000. Assetmark Inc. grew its position in Sarepta Therapeutics by 74.7% during the fourth quarter. Assetmark Inc. now owns 6,667 shares of the biotechnology company’s stock worth $643,000 after buying an additional 2,851 shares during the period. Finally, Trexquant Investment LP acquired a new position in Sarepta Therapeutics during the fourth quarter worth about $6,503,000. 91.82% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $126.87 on Friday. The company has a fifty day simple moving average of $106.17 and a two-hundred day simple moving average of $106.36. The company has a market cap of $11.87 billion, a price-to-earnings ratio of -16.20 and a beta of 0.93. The company has a quick ratio of 4.90, a current ratio of 5.44 and a debt-to-equity ratio of 1.62. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $159.89.

About Sarepta Therapeutics

(Get Free Report

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene.

Featured Stories

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.